Increasing prevalence of joint and bone diseases like osteoporosis,rheumatoid arthritis, and osteoarthritis is driving up the demand for autologousmatrix-induced chondrogenesis surgeries. This technology, which involves theinjection of stem cells into the patient's body, was initially developed inChina. Now it has gained popularity all over the world.
Autologous matrix-induced chondrogenesis is the process by which bones or cartilagesare implanted with stem cells from a patient's own body. The procedure involvesthe injection of stem cells into a large number of chondral lesions (which arelike fractures in the bone), where they will start to grow and form into newbone or cartilage. A large number of such autologous matrix-imprinted chondralsare now available for use in clinical trials for painful spinal cord injuriesand other uses.
The main constituents of autologous matrix-induced chondrogenesis includeglucosamine sulfate, amino acids, collagen, and hyaluronic acid. All of thesecompounds are produced naturally by our bodies, but they can be manufacturedand stored effectively in a medical formula through recent scientificdevelopments. One of the chief components of this manufacturing process is amixture of polylactic-co-glycolic acid (PCL) and polyethylene glycol (PEG).These mixtures stimulate the production of collagen, which replaces themoisture that has been removed during the manufacturing process of theautologous matrix.
Read More : https://bit.ly/3ybN0fL
